Development of olaparib for BRCA-deficient recurrent epithelial ovarian cancer

Clinical Cancer Research

Volumn 21, Issue 17, 2015, Pages 3829-3835

  Tewari, Krishnansu S ^a   Eskander, Ramez N ^a   Monk, Bradley J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEDIRANIB; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; TOPOTECAN; ANTINEOPLASTIC AGENT; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANEMIA; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG INDICATION; ENZYME INHIBITION; EUROPE; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GERMLINE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; NAUSEA; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PNEUMONIA; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; UNITED STATES; DEFICIENCY; FEMALE; GENETICS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRCA2 PROTEIN; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG APPROVAL; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES;

EID: 84942875194     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0088     Document Type: Article

References (27)

1. Tewari KS, Monk BJ. The 21st century handbook of clinical ovarian cancer. Heidelberg (Germany): Springer; 2015.
2. Eskander RN, Tewari KS. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol 2014; 7: 314-21.
3. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Merqui-Roelvink M, et a. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
4. Fong PC, Yap TA, Boss DS, Carden CP, Merqui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-9.
5. Yamamoto N, Nokihara H, Yamada Y, Toto Y, Tanioka M, Shibata T, et al. A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients withadvanced solid tumors. Cancer Sci 2012; 103: 504-9.
6. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumors. Br J Cancer 2011; 104: 750-5.
7. Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, et al. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib(AZD2281) incombination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs 2012; 30: 1493-500.
8. Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, et al. Aphase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18: 2344-51.
9. Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013; 15: R88.
10. Del Conte G, Sessa C, von Moos R, Vigano L, Digena T, Locatelli A, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumors. Br J Cancer 2014; 111: 651-9.
11. Balmana J, Tung NM, Isakoff SJ, Grana B, Ryan PD, Saura C, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian, and other solid tumors. Ann Oncol 2014; 25: 1656-63.
12. Bendell J, O'Reilly EM, Middleton MR, Chau I, Hoshster H, Fielding A, et al. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Ann Oncol 2015; 26: 804-11.
13. Chiou VL, Kohn EC, Annunziata CM, Minasian LM, Lipkowitz S, Yu M, et al. Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in heavily pretreated high-grade serous ovarian cancer (HGSOC) at low genetic risk (NCT01445418). J Clin Oncol 33, 2015 (suppl; abstr 5514).
14. Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, et al. Phase Istudy to assess the safety and tolerability ofolaparib in combination with bevacizumab in patients with advanced solid tumors. Br J Cancer 2012; 106: 468-74.
15. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A Phase I trial of the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013; 49: 2972-8.
16. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-44.
17. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245-51.
18. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-61.
19. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA 1/2 mutation. J Clin Oncol 2015; 33: 244-50.
20. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30: 372-9.
21. Ledermann J, Harter P, Gourlety C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-92.
22. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase II trial. Lancet Oncol 2014; 15: 852-61.
23. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase II trial. Lancet Oncol 2015; 16: 87-97.
24. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase II study. Lancet Oncol 2014; 15: 1207-14.
25. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonquay V, et al. Efficacy of chemotherapy in BRCA 1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res 2013; 19: 5485-93.
26. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764-75.
27. Banerjee S, Kaye SB, Ashworth A. Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010; 7: 508-19.